Latest News

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Sonrotoclax gains FDA approval as a promising treatment for relapsed mantle cell lymphoma, showcasing strong efficacy and safety in clinical trials.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

The NEO-CYT trial began treating patients with melanoma in the perioperative setting, combining a novel agent with immune checkpoint inhibitor therapy.

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Andrzej Jakubowiak, MD, PhD, explains promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple myeloma.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan has elicited antitumor activity across subtypes of extrapulmonary neuroendocrine carcinomas.

INBRX-106 may act as a costimulatory agent and enhance pembrolizumab outcomes in head and neck squamous cell carcinoma.

During a live event, Caitlin Costello, MD, discussed the tools used to evaluate risk status for smoldering myeloma.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

The FDA has approvesd zenocutuzumab-zbco for previously treated NRG1 fusion–positive cholangiocarcinoma cholangiocarcinoma.

FDA fast tracks RPTR-1.201, a TCR bispecific immunotherapy for advanced triple-negative breast cancer, as RaPTR-101 tests safety and early efficacy.

The FDA previously granted RZ-001 both orphan drug designation and fast track designation for hepatocellular carcinoma.

The phase 1/2 data led to the phase 3 RASolute 302 trial which supported the FDA's allowance of early access to daraxonrasib in PDAC.

Intraperitoneal rintatolimod may boost outcomes with immunotherapies such as pembrolizumab in ovarian cancer.

Robert Coleman, MD, discusses how relacorilant plus nab‑paclitaxel boosts survival in platinum‑resistant ovarian cancer.

Interim data from the LEGEND pivotal cohort show detalimogene achieved complete responses in more than half of patients with BCG-unresponsive non-muscle invasive bladder cancer.

First-in-class double-loaded patient-derived immunotherapy joins pancreatic cancer and glioblastoma in FDA Fast Track portfolio; phase 1/2 trial now recruiting.

Final PRIMO phase 2 data show oral duvelisib drives strong responses in relapsed PTCL, standout AITL benefit, with manageable safety signals.

Shagufta Shaheen, MD, discusses treatment strategies for pancreatic NETs.

Thomas LeBlanc, MD, reviews second-line options for lower-risk MDS after luspatercept failure, highlighting imetelstat’s efficacy, safety, and NCCN-aligned role.

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.

A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for biomarkers in ES-SCLC.